Gopalakrishna Harish, Ghany Marc G
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 10 Center Drive, Building 10, Room 9B-16, Bethesda, MD 20892-1800, USA.
Curr Hepatol Rep. 2024 Jun;23(2):241-252. doi: 10.1007/s11901-024-00652-9. Epub 2024 Feb 10.
Advancements in our understanding of the hepatitis B viral (HBV) life cycle have paved the way for novel approaches to treat HBV infection. This review summarizes the various strategies being pursued to achieve a functional cure, defined as loss of hepatitis B surface antigen (HBsAg) and absence of viral replication 6 months off-therapy.
Direct acting antiviral, host targeting antiviral, and immunological approaches are in various stages of development as treatment for chronic HBV infection.
Novel treatments are being developed in pursuit of a cure for HBV. Current evidence suggests a single therapeutic agent alone may be insufficient, necessitating the need for combination therapy targeting HBV and the host immune response. Ongoing research focused on identifying the best therapeutic combination holds promise in achieving functional cure for HBV.
我们对乙型肝炎病毒(HBV)生命周期认识的进展为治疗HBV感染的新方法铺平了道路。本综述总结了为实现功能性治愈所采用的各种策略,功能性治愈定义为停止治疗6个月后乙肝表面抗原(HBsAg)消失且无病毒复制。
直接作用抗病毒药物、宿主靶向抗病毒药物和免疫疗法正处于治疗慢性HBV感染的不同研发阶段。
正在研发新的治疗方法以治愈HBV。目前的证据表明,单一治疗药物可能不足,因此需要针对HBV和宿主免疫反应的联合治疗。正在进行的专注于确定最佳治疗组合的研究有望实现HBV的功能性治愈。